Shawn Keller
Payments from drug & device makers
Across 341 payments — averaging $23.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vanda Pharmaceuticals Inc.$1K
- Neurocrine Biosciences, Inc.$988
- AstraZeneca$800
- Gilead$640
- Alkermes, Inc.$432
- Teva Pharmaceuticals USA, Inc.$414
- plus $4K from 28 others
What the payments were for
- Food & beverage$7,930100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 42 | $1,051 |
| Neurocrine Biosciences, Inc. | 40 | $988 |
| AstraZeneca | 11 | $800 |
| Gilead | 25 | $640 |
| Alkermes, Inc. | 25 | $432 |
| Teva Pharmaceuticals USA, Inc. | 24 | $414 |
| AbbVie | 12 | $404 |
| Otsuka America Pharmaceutical, Inc. | 15 | $291 |
| Merck | 13 | $253 |
| GSK | 12 | $240 |
| Johnson & Johnson | 9 | $229 |
| Novo Nordisk | 9 | $216 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $188 |
| Boehringer Ingelheim | 6 | $157 |
| Corium, LLC | 12 | $156 |
| Amgen | 4 | $155 |
| Axsome Therapeutics, Inc. | 7 | $141 |
| Sunovion Pharmaceuticals Inc. | 9 | $139 |
| Actelion Pharmaceuticals US, Inc. | 1 | $117 |
| Indivior Inc. | 6 | $113 |
| Viiv Healthcare Company | 6 | $102 |
| Exact Sciences | 5 | $98 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $88 |
| Pharming Healthcare, Inc. | 4 | $81 |
| Biocryst US Sales Co., LLC | 4 | $80 |
| Lundbeck LLC | 5 | $75 |
| Lilly USA, LLC | 4 | $74 |
| Organon | 4 | $54 |
| Ironshore Pharmaceuticals Inc. | 3 | $45 |
| Dexcom, Inc. | 2 | $42 |
| Hologic Sales And Service, LLC | 1 | $20 |
| Abbott | 1 | $18 |
| Ardelyx, Inc. | 1 | $16 |
| Sun Pharmaceutical Industries Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,930 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 49 | $56,168 |
| TrulicityDulaglutide | 57 | $53,608 |
| JardianceEmpagliflozin | 59 | $45,689 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $44,587 |
| TradjentaLinagliptin | 50 | $30,645 |
| EliquisApixaban | 37 | $26,741 |
| OzempicSemaglutide | 20 | $20,828 |
| LinzessLinaclotide | 30 | $15,483 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $13,291 |
| JanuviaSitagliptin Phosphate | 13 | $9,614 |
| MyrbetriqMirabegron | 15 | $8,972 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $8,745 |
| FarxigaDapagliflozin Propanediol | 13 | $8,403 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $6,467 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $5,702 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $74 | $109,775106 claims |
| Boehringer IngelheimJardiance, Tradjenta | $157 | $76,334109 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $240 | $53,33288 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $800 | $21,69430 claims |
| Novo NordiskOzempic | $216 | $20,82820 claims |
| MerckJanuvia, Janumet | $253 | $16,08125 claims |
| AbbVieLinzess | $404 | $15,48330 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.
Other family in Houma
- Murray MorellaHouma$17K
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.